← Back to patent-cliff list
CAS 1198299-54-5
methyl 5-amino-4-(4-nitro-1-oxoisoindolin-2-yl)-5-oxopentanoate
Codes: LENA-020
Application context (from source-drug indications)
Marginal zone B-cell lymphomaLenalidomideFollicular lymphomaLenalidomideAdult T-cell leukaemia/lymphomaLenalidomideMantle cell lymphomaLenalidomideMyelodysplastic syndromeLenalidomideMultiple myelomaLenalidomide
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Lenalidomide | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione→4-nitroisoindolin-1-one→dimethyl 2-bromopentanedioate→dimethyl 2-(4-nitro-1-oxoisoindolin-2-yl)pentanedioate→methyl 5-amino-4-(4-nitro-1-oxoisoindolin-2-yl)-5-oxopentanoate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | methyl 2-(bromomethyl)-3-nitrobenzoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 3-aminopiperidine-2,6-dione hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.